1. bookVolume 58 (2020): Edizione 1 (March 2020)
Dettagli della rivista
License
Formato
Rivista
eISSN
2501-062X
Prima pubblicazione
30 Mar 2015
Frequenza di pubblicazione
4 volte all'anno
Lingue
Inglese
Accesso libero

Immunosuppressive treatment for peripheral neuropathies in Sjogren’s syndrome – a systematic review

Pubblicato online: 03 Mar 2020
Volume & Edizione: Volume 58 (2020) - Edizione 1 (March 2020)
Pagine: 5 - 12
Ricevuto: 01 Aug 2019
Dettagli della rivista
License
Formato
Rivista
eISSN
2501-062X
Prima pubblicazione
30 Mar 2015
Frequenza di pubblicazione
4 volte all'anno
Lingue
Inglese

1. FISHER B.A., BROWN R.M., BOWMAN S.J., BARONE F. A review of salivary gland histopathology in primary Sjögren’s syndrome with a focus on its potential as a clinical trials biomarker. Ann Rheum Dis. 2015; 74:1645–50.10.1136/annrheumdis-2015-20749926034044Search in Google Scholar

2. CHERIF E., BOUKHRIS I., HAJJI R., HASSINE LB., AZZABI S., KECHAOU I. et al. Extra-glandular manifestations of primary Sjögren’s syndrome. Eur J Intern Med. 2013; 24:e119.10.1016/j.ejim.2013.08.302Search in Google Scholar

3. ATTWOOD W., POSER CM. Neurologic complications of Sjogren’s syndrome. Neurology. 1961; 11:1034–41.10.1212/WNL.11.12.103413863143Search in Google Scholar

4. PAVLAKIS P.P., ALEXOPOULOS H., KOSMIDIS M.L., MAMALI I., MOUTSOPOULOS H.M., TZIOUFAS A.G. et al. Peripheral neuropathies in Sjögren’s syndrome: A critical update on clinical features and pathogenetic mechanisms. J Autoimmun. 2012; 39:27–33.10.1016/j.jaut.2012.01.00322318209Search in Google Scholar

5. MARGARETTEN M. Neurological manifestations of primary Sjögren’s syndrome. Reumatologia. 2018; 56:99–105.10.5114/reum.2018.75521597463229853725Search in Google Scholar

6. DELALANDE S., DE SEZE J., FAUCHAIS A.-L., HACHULLA E., STOJKOVIC T., FERRIBY D. et al. Neurologic manifestations in primary Sjögren syndrome. Medicine (Baltimore). 2004; 83:280–91.10.1097/01.md.0000141099.53742.1615342972Search in Google Scholar

7. MOROZUMI S., KAWAGASHIRA Y., IIJIMA M., KOIKE H., HATTORI N., KATSUNO M. et al. Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjögren’s syndrome. J Neurol Sci. 2009; 279:57–61.10.1016/j.jns.2008.12.01819168191Search in Google Scholar

8. LEVY Y., UZIEL Y., ZANDMAN G.G., AMITAL H., SHERER Y., LANGEVITZ P. et al. Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. Ann Rheum Dis. 2003; 62:1221–3.10.1136/ard.2002.003996175438514644864Search in Google Scholar

9. MOCHIZUKI H., KAMAKURA K., MASAKI T., HIRATA A., NAKAMURA R., MOTOYOSHI K. Motor dominant neuropathy in Sjoegren’s syndrome: Report of two cases. Intern Med. 2008; 41:142–6.10.2169/internalmedicine.41.14211868603Search in Google Scholar

10. FONT J., RAMOS-CASALS M., DE LA RED G., POU A., CASANOVA A., GARCIA-CARRASCO M. et al. Pure sensory neuropathy in primary Sjögren’s syndrome. Longterm prospective followup and review of the literature. J Rheumatol. 2003; 30:1552–7.Search in Google Scholar

11. RIST S., SELLAM J., HACHULLA E., SORDET C., PUECHAL X., HATRON P. et al. Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren’s syndrome: A national multicentric retrospective study. Arthritis Care Res (Hoboken). 2011; 63:1339–44.10.1002/acr.2049521584943Search in Google Scholar

12. PERTOVAARA M., KORPELA M. Sustained response to rituximab in a patient with Sjögren´s syndrome and severe refractory polyneuropathy. Clin Exp Rheumatol. 2012; 30:808.Search in Google Scholar

13. MEKINIAN A., RAVAUD P., HATRON P.Y., LARROCHE C., LEONE J., GOMBERT B. et al. Efficacy of rituximab in primary Sjogren’s syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis. 2012; 71:84–7.10.1136/annrheumdis-2011-20008621926185Search in Google Scholar

14. MIN J.K., PARK K.S., YU W.J., LEE Y.S., PARK S.M., PARK S.H. et al. Systemic mononuclear inflammatory vasculopathy associated with Sjögren’s syndrome in a patient with primary biliary cirrhosis. Korean J Intern Med. 2000; 15:89–92.10.3904/kjim.2000.15.1.89453175110714099Search in Google Scholar

15. SHIMOYAMA M., OHTAHARA A., OKAMURA T., WATANABE M., FUJIMOTO Y., TESHIMA S. et al. Isolated autonomic cardiovascular neuropathy in a patient with primary Sjögren syndrome: a case of successful treatment with glucocorticoid. Am J Med Sci. 2002; 324:170–2.10.1097/00000441-200209000-0001012240717Search in Google Scholar

16. DUPOND J.L., GIL H., DE WAZIERES B. Five-year efficacy of intravenous gammaglobulin to treat dysautonomia in Sjögren’s syndrome. Am J Med. 1999; 106:125.Search in Google Scholar

17. PASCUAL J., CID C., BERCIANO J. High-dose i.v. immunoglobulin for peripheral neuropathy associated with Sjögren’s syndrome. Neurology. 1998; 51:650–1.10.1212/WNL.51.2.650-bSearch in Google Scholar

18. KIZAWA M., MORI K., IIJIMA M., KOIKE H., HATTORI N., SOBUE G. Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sjögren’s syndrome. J Neurol Neurosurg Psychiatry. 2006; 77:967–9.10.1136/jnnp.2005.084533207761316844955Search in Google Scholar

19. MOLINA J.A., BENITO-LEÓN J., BERMEJO F., JIMÉNEZ-JIMÉNEZ F.J., OLIVÁN J. Intravenous immunoglobulin therapy in sensory neuropathy associated with Sjögren’s syndrome. J Neurol Neurosurg Psychiatry. 1996; 60:699.10.1136/jnnp.60.6.69910739668648349Search in Google Scholar

20. TAKAHASHI Y., TAKATA T., HOSHINO M., SAKURAI M., KANAZAWA I. Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjögren’s syndrome. IV immunoglobulin. Neurology. 2003; 60:503–5.10.1212/01.WNL.0000046680.47883.7DSearch in Google Scholar

21. MORI K., IIJIMA M., KOIKE H., HATTORI N., TANAKA F., WATANABE H. et al. The wide spectrum of clinical manifestations in Sjögren’s syndrome-associated neuropathy. Brain. 2005; 128:2518–34.10.1093/brain/awh60516049042Search in Google Scholar

22. GORSON K.C., NATARAJAN N., ROPPER A.H., WEINSTEIN R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: A prospective pilot trial. Muscle Nerve. 2007; 35:66–9.10.1002/mus.2066416967492Search in Google Scholar

23. BOTEZ S.A., HERRMANN D.N. Prolonged remission of a demyelinating neuropathy in a patient with lymphoma and Sjögren’s syndrome after Rituximab therapy. J Clin Neuromuscul Dis. 2010; 11:127–31.10.1097/CND.0b013e3181c5051320215986Search in Google Scholar

24. MEIJER J.M., MEINERS P.M., VISSINK A., SPIJKERVET F.K.L., ABDULAHAD W., KAMMINGA N. et al. Effectiveness of rituximab treatment in primary Sjögren’s syndrome: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010; 62:960–8.10.1002/art.2731420131246Search in Google Scholar

25. VOULGARELIS M., GIANNOULI S., TZIOUFAS A.G., MOUTSOPOULOS H.M. Long term remission of Sjogren’s syndrome associated aggressive B cell non-Hodgkin’s lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis. 2006; 65:1033–7.10.1136/ard.2005.046193179823516322082Search in Google Scholar

26. MOHER D., LIBERATI A., TETZLAFF J., ALTMAN D.G., GROUP T.P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med. 2009; 6:e1000097.10.1371/journal.pmed.1000097270759919621072Search in Google Scholar

27. WAKASUGI D., KATO T., GONO T., ITO E., NODERA H., KAWAGUCHI Y. et al. Extreme efficacy of intravenous immunoglobulin therapy for severe burning pain in a patient with small fiber neuropathy associated with primary Sjögren’s syndrome. Mod Rheumatol. 2009; 19:437–40.10.3109/s10165-009-0180-2Search in Google Scholar

Articoli consigliati da Trend MD

Pianifica la tua conferenza remota con Sciendo